Triple-Negative Breast Cancer: Molecular Drivers and Emerging Precision Therapies

This is a concise, self-written medical summary of Triple-Negative Breast Cancer (TNBC), one of the most aggressive breast cancer subtypes. The article explains key molecular drivers, including genetic mutations, immunogenicity, and tumor heterogeneity, and summarizes emerging precision therapies such as PARP inhibitors, immune checkpoint inhibitors, and antibody–drug conjugates.

The work demonstrates skills in scientific writing, critical analysis, and translating complex biomedical information into a clear, structured format suitable for both professional and broader audiences.